Mustafa ÖZBEK, Selvihan BEYSEL, Erman ÇAKAL, Muhammed KIZILGÜL, Mustafa ÇALIŞKAN

Effect of parathyroidectomy on epicardial fat thickness as a cardiovascular risk factor in patients with primary hyperparathyroidism

Background/aim: Several studies demonstrated that primary hyperparathyroidism is related to increased risk for cardiovasculardiseases (CVDs), and risk is decreased by parathyroidectomy. Epicardial fat thickness (EFT) has been postulated as a new marker ofCVD risk. We evaluated the impact of parathyroidectomy on EFT in patients with primary hyperparathyroidism (PHPT).Materials and methods: Thirty-four PHPT patients (29 female, 5 male) and 28 age- and sex-matched controls (19 female, 9 male)were included in the study. Demographic, anthropometric, and biochemical data were recorded both before parathyroidectomy and 6months after the procedure. Epicardial fat thickness was measured by transthoracic echocardiography.Results: Mean age was 53.15 ± 8.44 years. Mean preoperative EFT was higher than mean EFT in the control group (0.49 ± 0.07 cmto 0.46 ± 0.08 cm, P: 0.0005), and EFT decreased after parathyroidectomy (0.49 ± 0.07 cm to 0.44 ± 0.08 cm, P: 0.0005). Systolicblood pressure and calcium, parathormone, and hsCRP levels decreased after parathyroidectomy (P < 0.05). Vitamin D levels increased(P < 0.05). Diastolic blood pressure, body mass index, carotid intima-media thickness, and HOMA-IR, fasting plasma glucose, andphosphorus levels were unchanged after parathyroidectomy (P > 0.05). Preoperatively, EFT was correlated with SBP (r: 0.360, P: 0.0285)and age (r: 0.466, P: 0.0036). Multiple linear regression used to identify independent predictors of change in epicardial fat did not findany predictor of change in epicardial fat (P > 0.05).Conclusion: EFT was decreased by parathyroidectomy in patients with primary hyperparathyroidism. However, the decrease in EFTwas not correlated with any of the cardiovascular risk factors. More comprehensive studies evaluating the potential relation betweenPHPT and EFT need to be conducted.

PDF

___

1. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. British Medical Journal 2015; 350: h2723. doi: 10.1136/bmj.h2723
2. Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C et al. Primary hyperparathyroidism. Nature Reviews Disease Primers 2016; 2: 16033. doi: 10.1038/nrdp.2016.33
3. Smith JC, Page MD, John R, Wheeler MH, Cockcroft JR et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2000; 85 (10): 3515-3519.
4. Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clinical Endocrinology 2010; 73 (1): 30-34. doi: 10.1111/j.1365-2265.2009.03766.x
5. Nilsson IL, Åberg J, Rastad J, Lind L, Clark OH et al. Circadian cardiac autonomic nerve dysfunction in primary hyperparathyroidism improves after parathyroidectomy. Surgery 2003; 134 (6): 1013-1019.
6. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clinical Endocrinology 1999; 50 (3): 321-328.
7. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. Journal of Clinical Endocrinology and Metabolism 1997; 82 (1): 106-112.
8. Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Current Opinion in Cardiology 2013; 28 (4): 458-463. doi: 10.1097/HCO.0b013e3283605fba
9. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. Journal of the American Society of Echocardiography 2009; 22 (12): 1311- 1319. doi: 10.1016/j.echo.2009.10.013
10. Lima-Martínez MM, Blandenier C, Iacobellis G. Epicardial adipose tissue: more than a simple fat deposit? Endocrinology 2013; 60 (6): 320-328. doi: 10.1016/j.endonu.2012.08.001
11. Bilezikian JP, Potts JT Jr, Fuleihan GH, Kleerekoper M, Neer R et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism 2002; 87 (12): 5353-5361.
12. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obesity Research 2003; 11 (2): 304-310.
13. Mazurek T, Zhang LF, Zalewski A, Mannion JD, Diehl JT et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108 (20): 2460-2466.
14. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends in Endocrinology and Metabolism 2000; 11 (8): 327-332.
15. Sacks HS, Fain JN, Bahouth SW, Ojha S, Frontini A et al. Adult epicardial fat exhibits beige features. Journal of Clinical Endocrinology and Metabolism 2013; 98 (9): E1448-1455. doi: 10.1210/jc.2013-1265
16. Salazar J, Luzardo E, Mejías JC, Rojas J, Ferreira A et al. Epicardial fat: physiological, pathological, and therapeutic implications. Cardiology Research and Practice 2016; 2016: 1291537. doi: 10.1155/2016/1291537
17. Matloch Z, Kotulak T, Haluzik M. The role of epicardial adipose tissue in heart disease. Physiological Research 2016; 65 (1): 23-32.
18. Iacobellis G. Epicardial adipose tissue in endocrine and metabolic diseases. Endocrine 2014; 46 (1): 8-15. doi: 10.1007/ s12020-013-0099-4
19. Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovascular Research 1998; 37 (1): 34-41.
20. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Current Osteoporosis Reports 2008; 6 (2): 77-83
21. Silverberg SJ. Editorial: Cardiovascular disease in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2000; 85 (10): 13-14.
22. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease—a review. European Heart Journal 2004; 25 (20): 1776-1787.
23. Akhabue E, Thiboutot J, Cheng JW, Vittorio TJ, Christodoulidis G et al. New and emerging risk factors for coronary heart disease. American Journal of the Medical Sciences 2014; 347 (2): 151-158. doi: 10.1097/MAJ.0b013e31828aab45
24. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clinical Cornerstone 2007; 8 (3): 11-28.
25. Walker MD, Fleischer J, Rundek T, McMahon DJ, Homma S et al. Carotid vascular abnormalities in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2009; 94 (10): 3849-3856. doi: 10.1210/jc.2009- 1086
26. Ljunghall S, Palmer M, Akerstrom G, Wide L. Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy. European Journal of Clinical Investigation 1983; 13 (5): 373-377.
27. Almqvist EG, Bondeson AG, Bondeson L, Svensson J. Increased markers of inflammation and endothelial dysfunction in patients with mild primary hyperparathyroidism. Scandinavian Journal of Clinical and Laboratory Investigation 2011; 71 (2): 139-144. doi: 10.3109/00365513.2010.543694
28. Luigi P, Chiara FM, Laura Z, Cristiano M, Giuseppina C et al. Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. International Journal of Endocrinology 2012; 2012: 408295. doi: 10.1155/2012/408295
29. Asik M, Sahin S, Temiz A, Ozkaya M, Ozkul F et al. Evaluation of epicardial fat tissue thickness in patients with primary hyperparathyroidism. Endocrine Practice 2014; 20 (1): 26-32. doi: 10.4158/EP13140.OR